The pharmaceutical contract manufacturer Wuxi Griffin Pharmaceutical is a new joint venture between Wuxi Fortune Pharmaceutical in China and SialoCarb, a private company based in Eslöv, Sweden that specialises in sterile filling and medical device validation and production.
The main focus of the western-managed joint venture is aseptic fill & finish of sterile pharmaceuticals.
Headed by CEO Torgny Lundgren, Wuxi Griffin Pharmaceutical's management says it has extensive knowledge in the pharmaceutical business with an average of 15 years of experience.
Of the new venture, Lundgren, said :"There has been a lack of knowhow of how to implement western manufacturing GMP standards in China and this gap is filled by the new plant in Wuxi, China."
China is the second largest market for pharmaceuticals and with the highest growth rate, Western pharmaceutical companies therefore need to be in China to expand.
Products manufactured in the new Wuxi facility include MAbs, vaccine, recombinant proteins as well as biosimilars and small molecule drugs (traditional).
RABS and Isolator production technology is used, and there is capacity for manufacturing of clinical trials for biologics (small and medium sized batches) as well as commercial manufacturing.
"Complying to global GMP gives us an advantage as the requirements of Chinese customers wanting Western quality products are met. We also assist Western pharmaceutical companies wanting accelerated access to the Chinese market," added Lundgren.
